Table 1: Reports of carboplatin-induced syndrome of inappropriate of antidiuretic hormone secretion.
|
Reporter |
Age/Sex |
Tumor type |
Chemotherapy regimen |
Nadir serum sodium level (m Eq/L) |
Next treatement for tumor |
|
Yokoyama |
63/F |
Ovarian cancer |
CBDCA + PTX |
109 |
CDDP + PTX |
|
Fujioka |
60/F |
Lung cancer |
CBDCA + PTX |
101 |
No record |
|
Turner |
49/F |
Breast cancer |
CBDCA + DTX + HER |
105 |
DTX + HER (without CBDCA) |
|
Sugiyama |
66/F |
Urethral cancer |
CBDCA + PTX |
No record |
Continue (SIADH was controllable) |
|
Our case |
77/F |
Ovarian cancer |
CBDCA + DTX + BEV |
115 |
CBDCA + DTX (weekly regimen) |
CBDCA: Carboplatin; PTX: Paclitaxel; CDDP: Cisplatin; DTX: Docetaxel; HER: Trastuzumab; SIADH: Syndrome of inappropriate antidiuretic hormone secretion; BEV: Bevacizumab; BSC: Best supportive care.